ClinicalTrials.gg
CompletedNCT06157450Updated Dec 5, 2023

Pharmacokinetics of ZSP1273 in Elder Participants

A Phase 1 interventional study of ZSP1273 in Elder, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and PK of ZSP1273 in elder Participants

02

Conditions studied

  • Elder
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signature of a dated Form (ICF) indicating that the participates has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
  2. Participants must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  3. Body weight is no less than 50 kg in males and no less than 45 kg in females. (BMI) 18≤BMI\<28 kg/m2,BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
  4. Heart rate between 50-100 beats/min, Body temperature between 35.7-37.5℃

    Young Participants Only:

  5. Participants must be ≥18 to ≤45 years old

    Elder Participants Only:

  6. Participants must be ≥65 years old

Exclusion criteria

Exclusion Criteria:

  1. Participants with an allergic disposition (multiple drug and food allergies)
  2. Participants who donated blood or bleeding profusely (> 400 mL) in the 3 months.
  3. Participants with disease, such as gastrointestinal disease, infection (e.g., respiratory or central nervous system infection), within 2 weeks before screening;
  4. Participants who could not tolerate blood collection by venipuncture and/or had a history of dizzy with blood and needles

    Young Participants Only:

  5. Participants had taken or planned to take any prescription medication, over-the-counter medication, vitamin product, or herbal medicine within 2 weeks before screening;
  6. Physical examination, vital signs, laboratory tests (blood routine +CRP, urine routine + urine sediment, blood biochemistry, coagulation function, infectious disease test, glycosylated test), 12-lead , chest CT, abdominal color Doppler ultrasound and other examinations have clinical significance

    Elder Participants Only:

  7. Participants had a history of or evidence of cardiovascular disease before screening: uncontrolled hypertension, orthostatic hypotension, severe arrhythmia, heart failure, Adams-stokes syndrome, unstable angina, myocardial infarction within the past 6 months before screening, or history of tachycardia/bradycardia requiring medical treatment, and degree II-III atrioventricular block.
  8. Participants who had other serious organ-systemic serious diseases at screening, including but not limited to respiratory, neurologic, hematologic, endocrine, oncologic, immunologic, psychiatric, or cardio-cerebrovascular diseases, and was judged by the investigator to be ineligible for participation in the trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Experimental: young participates

    16 young participants(between 18\~45 years old) will be given 600mg of ZSP1273.

    Drug: ZSP1273

  • Experimental
    Experimental:elder participates

    16 elder participants(Age≥65 years old) will be given 600mg of ZSP1273.

    Drug: ZSP1273

Interventions

  • Participants receive ZSP1273 orally.

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    The Cmax of a single dose of ZSP1273 in elder participants and young participates will be evaluated and compared.

    Time frame: Day 1 to Day 5

  2. Area under the concentration-time curve from time zero to infinity (AUCinf)

    The AUCinf of a single dose of ZSP1273 in elder participants and young participates will be evaluated and compared.

    Time frame: Day 1 to Day 5

  3. Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUClast)

    The AUClast of a single dose of ZSP1273 in elder participants and young participates will be evaluated and compared.

    Time frame: Day 1 to Day 5

Secondary outcomes

  1. Number of participants with drug-related adverse events as assessed by CTCAE v5.0

    Time frame: Day 1 to Day 5

07

Study locations

1 site
  • Sir Run Run Hospital
    Nanjing, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Dec 5, 2023
StartActual
Oct 11, 2023
Primary completionActual
Nov 1, 2023
CompletionActual
Nov 17, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06157450
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Oct 11, 2023
Primary completion
Nov 1, 2023
Completion
Nov 17, 2023
Last update
Dec 5, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion